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A B S T R A C T
The dramatic increase in the world's population that has occurred over the past 100
years has come largely through reductions in death due to infectious disease. An epi-
demiologic transition to a preponderance of deaths due to degenerative conditions such
as cardiovascular disease and cancer is occurring in the developing countries as well as
in the industrialized ones. In the industrialized countries, demographic profiles now re-
flect the increased life expectancies of both sexes. However, female life expectancies ex-
ceed male by six or more years. Further change in mortality patterns will accompany
success in the reduction of the number of mortalities attributable to such degenerative
conditions as cardiovascular disease and cancer. In the 21st century, conditions associ-
ated with senescence will be of increasing concern. Adaptive strategies that enhanced re-
productive success throughout most of human evolution may now prove detrimental to
human health as average life expectancies reach unprecedented length. In this environ-
ment, differences in the survival mechanisms deployed by males as opposed to females
will become increasingly important.
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Introduction
That males and females are different
is an obvious fact. However, the extent of
the biological differences between the
sexes is greater than generally appreci-
ated. In fact, many otherwise well-de-
signed biomedical research projects have
been designed as though the sexes were
identical. Thus, for instance, most of what
is known about the etiology of heart dis-
ease has, until quite recently, been lear-
ned from research done largely on male
populations. Often, the dosage of medica-
tions prescribed for patients of either sex
has been determined by the results of
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clinical trials conducted with male sub-
jects with the only adjustments being for
body weight. With major initiatives in re-
search on women's health issues, some of
the hazards of this approach are being
recognized and corrective measures taken.
Along with the improvements in medical
care that these initiatives have gener-
ated, has been expanded understanding
of the magnitude of human sex differen-
ces1.
The evolutionary implications of hu-
man sexual dimorphism clearly deserve
the attention of human biologists. The
adaptive strategies of human populations
under various forms of environmental
stress have been the focus of numerous
studies in which epigenetic adjustments
made to accommodate challenges such as
malnutrition have been shown to differ in
males and females2,3. Sexual differences
in mortality rates throughout the human
life cycle are well known, although not
fully understood.
It has only been within the past 50
years that the average life expectancy
has approached the biblical three score
and ten years. In modern, industrialized
societies, women live longer than men.
This was not always the case. Nor is it
the case everywhere today. In both past
and present populations where the life
expectancies of women are short, there is
a strong negative correlation between fe-
male life expectancy and fertility. Bear-
ing children is a stressful, biologically ex-
pensive process. Natural selection has fa-
vored physiological mechanisms that en-
able women to cope with the demands of
reproduction. The selective pressures as-
sociated with these demands tend to am-
plify the elements of sexual dimorphism
that give rise to these mechanisms. These
mechanisms provided the margin of sur-
vival over thousands of generations of hu-
man evolution during which survival be-
yond the reproductive years was uncom-
mon. It is only very recently that the po-
tential costs of these mechanisms later in
life have become manifest, as larger num-
bers of women have lived long enough to
experience them.
The trend of increasing life expectancy
started in the western industrial coun-
tries during the 19th century and has,
with a few notable exceptions, gradually
spread throughout the world. The areas
in which reversals of this trend have oc-
curred are those where a combination of
rapidly spreading infectious disease and
civil unrest has produced extraordinary
mortality rates among the reproducing
and pre-reproducing segments of the po-
pulation4. In such areas it is possible to
find examples of negative population
growth despite high fertility rates. How-
ever, it is likely that this situation is a
temporary one and that the worldwide
trend will continue for a time. The trend
has, in large part, been attributable to
technological advances in the prevention
and treatment of infectious disease. Re-
cent advances in the prevention and
treatment of cardiovascular diseases and
cancer may significantly alter the mortal-
ity pattern for future generations. How-
ever, since their life extending benefits
are most often experienced in the middle
and late years of the life span, their im-
pact on the fertility rate will be more
limited5.
Several investigators have attempted
to use current demographic and epidemi-
ological trends to predict future life ex-
pectancy6. They have concluded that even
if it is possible to eliminate all heart dis-
ease and cancer mortality, the limits of
human longevity will come into play and
average life expectancy will never exceed
100 years. They do not, however attempt
to predict what the leading causes of mor-
tality will be in the middle of the 21st cen-
tury. While acknowledging that advances
in biomedical science including promising
breakthroughs in tissue engineering
make any such predictions risky indeed,
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the present study will attempt to high-
light some aspects of the aging process,
among them some that differ according to
sex, that may represent intrinsic limits to
the human life span7,8. Viewed from this
perspective, conditions such as osteoporo-
sis, never included among the leading
causes of mortality, may be recognized as
potentially significant contributors to
morbidity and mortality in future popula-
tions.
Current demographic trends
Largely due to the increase in life ex-
pectancy, the past century has been mar-
ked by an unprecedented increase in the
world’s population. Although reductions
in deaths attributed to infectious disease
have been a major factor in this increase,
a small number of diseases, such as ma-
laria, schistosomiasis, and trypanosomia-
sis, continue to pose a serious threat to
human survival in specific geographical
areas. The influenza virus continues to
produce new variants although none
have attained the degree of virulence ex-
hibited by the strain associated with the
worldwide 1918 pandemic. Other disea-
ses, such as tuberculosis and certain stre-
ptococcal infections, have shown signs of
becoming resistant to conventional medi-
cations and therefore remain a serious
concern. Recently, still other disease enti-
ties such as the HIV and Ebola viruses
have emerged. There is, in fact, consider-
able evidence that claims of victory in the
war against infectious disease were, at
best, premature. Nevertheless, there
have been significant changes in the pat-
terns of human mortality. A sharp decline
in the number of premature deaths asso-
ciated with infectious disease has restru-
ctured the world’s demographic profile9.
As already mentioned, the trend to-
ward reduced early mortality has been in
progress the longest in the industrialized
nations. In these countries, socioecono-
mic factors associated with reduced in-
fant mortality have operated to reduce
fertility concurrently with increases in
life expectancy. The result has been a de-
cline in birth rates to a point where they
are now below replacement level. Table
110 shows life expectancies, infant mortal-
ity rates and fertility rates of seven Euro-
pean countries. Note that life expectan-
cies for women in these countries are all
more than 77 years, while male life ex-
pectancies average 6.4 years less. None of
these seven countries has a fertility rate
approaching the 2.0 needed for replace-
ment of the present reproductive popula-
tion. With fewer people entering the re-
producing segment of these populations,
and with more entering the elderly seg-
ment, their demographic profiles are all,
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TABLE 1
SEX RATIOS, LIFE EXPECTANCIES, INFANT MORTALITY AND FERTILITY OF SEVEN
INDUSTRIALIZED COUNTRIES
Country Popula-
tion
(1000's)
Popula-
tion un-
der 15%
Growth
rate
%/year
Sex
ratio
Life expectancy Infant
morta-
lity
Total
fertilityMale Female
Austria 8,161 17.7 0.86 103 72.8 79.3 7 1.47
Denmark 5,248 17.5 0.32 102 72.5 77.8 8 1.75
France 56,543 19.4 0.48 105 73.8 82.4 7 1.70
Germany 82,190 16.1 0.55 104 72.6 79.1 6 1.30
Italy 57,240 15.0 0.06 106 74.2 80.6 8 1.24
Netherlands 15,661 18.3 0.66 102 74.1 80.2 6 1.59
United Kingdom 58,201 19.3 1.00 104 73.7 79.0 7 1.78
to varying degrees, departing from the
broad-based pyramidal form characteris-
tic of young, dynamic populations.
The epidemiologic transition
Along with the reduced mortalities to
infectious diseases experienced by popu-
lations undergoing the demographic tran-
sition has been an increase in the propor-
tion of the population dying of so-called
degenerative conditions such as cardio-
vascular disease and cancer. Table 2 com-
pares the leading causes of death in the
developed and the developing countries
in 1990. Note that although ischemic
heart disease is the leading cause of death
in the industrialized countries, killing
2,695,000 people and accounting for 24.7%
of all deaths, more people (3,565,000) die
of this cause in the developing countries.
The total number of deaths attributable
to ischemic heart disease and cerebrovas-
cular disease that year in the developed
nations was 4,122,000, 52.5% of all mor-
talities. In the developing countries,
6,519,000 people died of these two causes
accounting for 45.3% of all mortalities.
Thus, although there is a tendency to re-
gard cardiovascular disease as one of »the
diseases of industrialized civilization« it
accounts for nearly half of all deaths in
the developing countries as well. More-
over, mortalities due to cardiovascular
disease are increasing in the developing
countries at the same time they are de-
creasing in the developed ones. As can be
seen in the comparisons in Table 2, can-
cer accounts for a far higher proportion of
deaths in the industrialized nations.
However, the disparity in the proportion
of deaths attributable to some form of
cancer does not signal an epidemic of can-
cer in industrialized nations. Instead,
both the absolute and relative increases
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TABLE 2
THE 10 LEADING CAUSES OF DEATH IN 1990 – DEVELOPED AND DEVELOPING REGIONS
COMPARED
Developed Regions Developing Regions
Cause of death Deaths
(1000's)
Cumula-
tive %
Cause of death Deaths
(1000's)
Cumula-
tive %
All causes 10,912 All Causes 39,554
1. Ischemic heart
disease
2,695 24.7 1. Lower respiratory
infections
3,915 9.9
2. Cerebrovascular
disease
1,427 37.8 2. Ischemic heart
disease
3,565 18.9
3. Trachea, bronchus,
and lung cancer
523 42.6 3. Cerebrovascular
disease
2,954 26.4
4. Lower respiratory
infections
385 46.1 4. Diarrheal disease 2,940 33.8
5. Chronic obstructive
pulmonary disease
324 49.1 5. Conditions connected
with childbirth
2,361 38.7
6. Colon and rectal
cancers
277 51.6 6. Tuberculosis 1,922 43.4
7. Stomach cancer 241 53.8 7. Chronic obstructive
pulmonary disease
1,887 46.1
8. Road traffic accidents 222 55.8 8. Measles 1,058 48.7
9. Self-inflicted injuries 193 57.6 9. Malaria 856 50.9
10. Diabetes mellitus 176 59.2 10. Road traffic accidents 777 52.8
in cancer mortality can be explained by
the increase in the proportion of the pop-
ulation surviving into the later, cancer-
prone stages of life.
Presumably, the number of deaths
caused by such diseases as lower respira-
tory infection, diarrhea, diseases associ-
ated with childbirth, tuberculosis, mea-
sles and malaria will decline in the fore-
seeable future. All told these diseases
now account for almost 32% of the deaths
occurring in the developing world. As
these diseases come under control, many
people whose lives are spared will live
long enough to become candidates for
cancer or heart disease. Although it is
possible that the epidemiological transi-
tion that has taken place in the developed
countries will be replicated over time in
the developing nations, a variety of fac-
tors may intervene to produce a different
pattern than that seen in Europe, Japan
and the United States today. A question
of considerable interest is: what will be
the primary causes of mortality in non-in-
dustrialized countries if and when mor-
talities due to infectious disease in devel-
oping countries have been reduced to the
level now observed in industrialized na-
tions? The answer to this question has
been the subject of intense scrutiny by
epidemiologists11. This is because, in ad-
dition to changes in rates of incidence and
prevalence for major diseases, the demo-
graphic profile has also changed. Conse-
quently, the standard population used as
the basis for projections of future mortal-
ity rates is sufficiently different to yield
substantially different results. An illus-
tration of the effect of using different
sample populations for projections of fu-
ture mortalities can be seen in Table 3.
As can be seen in Table 3, use of a
sample population wherein the age struc-
ture is strongly influenced by the inclu-
sion of substantially more individuals in
the later stages of the life cycle yields dif-
ferent expectations of mortality due to
most causes. Notable are significant re-
ductions in deaths due to atherosclerosis
and cardiovascular diseases and increa-
ses in those attributable to chronic ob-
structive pulmonary disease, pneumonia
and influenza, diabetes, and Alzheimer's
disease. In reality, death due to cardio-
vascular disease has been decreasing in
frequency in the United States since
about 1960. This decline, along with that
for death due to chronic liver disease pro-
vide evidence that the long-cited trend of
replacement of infectious disease by chro-
nic degenerative conditions as leading
causes of mortality is more complicated
than once thought. Also somewhat sur-
prising is the relative stability in the
number of cancer deaths. The inevitable
question that arises when these statistics
are examined is: what will be the leading
causes of death in the middle of the 21st
century? There is no clear trend to pro-
vide a ready answer to this question. A
related question is: will the trend toward
increasing life expectancies continue in-
definitely? Some possible answers to
these questions will be explored later in
this discussion, but first, another aspect
of the changing demographic profile in
one industrial country, the United States,
will be examined from another perspec-
tive, namely that of the projected remain-
ing years of life at a given age. Clearly,
this is a more realistic estimator of life
expectancy than the more often cited life
expectancy at birth. This is true in part
because the disproportionately hazard-
ous first year of life can be excluded from
the calculation for the later years. Exami-
nation of the data in Table 412 will illus-
trate this point.
As can be seen in Table 4, beyond age
20, the male increment in predicted age
at death exceeds the female increment at
every age. The disparity increases with
increasing age. For instance, in 1996, the
projected age at death for women of all
races aged 20 years in the United States
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was 79.9 years. For males of the same
age, the projected age at death that year
was 74.2 years. However, at age 85, the
projected age at death for women was
91.4 years, and that for men was 90.4
years. The narrowing of the life expec-
tancy gap appears to accelerate from age
55 onward. Coincidentally, this is the age
when the level of circulating estrogens
usually declines sharply in women. The
changes in body composition associated
with reduced sex steroid secretion in both
28
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TABLE 3
ESTIMATED NUMBER OF DEATHS PER 100,000 POPULATIONS ATTRIBUTED TO VARIOUS CAUSES
USING 1940 AND 2000 UNITED STATES POPULATION PROFILES FOR ESTIMATION
Cause of death 1979 1985 1990 1995 % change
All causes
1940 577.1 548.8 520.2 503.9 –12.7
2000 1,011.1 988.1 938.7 918.5 –9.2
Heart disease
1940 199.6 181.4 152.0 138.3 –30.7
2000 401.7 374.9 332.1 296.3 –26.2
Malignant neoplasms
1940 130.8 134.4 135.0 129.9 –0.7
2000 204.0 211.3 216.0 211.7 +3.8
Cerebro–vascular disease
1940 41.6 32.5 27.7 26.7 –35.8
2000 97.3 76.6 65.5 63.9 –34.3
Chronic obstructive pulmonary disease
1940 14.6 18.8 19.7 20.8 +42.9
2000 25.5 34.5 37.2 40.5 +56.7
Pneumonia & influenza
1940 11.2 13.5 14.0 12.9 +15.6
2000 26.1 34.5 36.8 33.8 +29.4
Diabetes mellitus
1940 9.8 9.7 11.7 13.3 +36.1
2000 17.5 17.4 20.7 23.4 +33.8
HIV
1940 0 0 9.8 15.6 +184.2
2000 0 0 10.2 16.4 +189.8
Alzheimer's disease
1940 0.3 1.6 2.2 2.7 +980.0
2000 0.4 4.1 6.4 8.4 +1862.8
Atherosclerosis
1940 5.7 4.0 2.8 2.3 –58.4
2000 17.9 12.6 8.5 6.9 –61.5
Chronic liver disease
1940 12.1 9.7 8.6 7.6 –37.0
2000 14.8 12.3 10.7 10.0 –32.8
Data from Anderson and Rosenberg (1998)12
sexes involve the loss of bone and skeletal
muscle. The result of this loss is an in-
crease in the ratio of fat to total body
mass. The relationship of this decline in
lean body mass to mortality risk is a mat-
ter of special interest in populations
where life expectancies have increased
the most.
The results of a number of studies pro-
vide evidence that unintended weight
loss, particularly loss of muscle mass, is
an indicator of increased risk of mortality
in older individuals. There are many rea-
sons for this being the case. Some of the
proposed explanations implicate compro-
mised immune competence13. A compre-
hensive review of these explanations is
beyond the scope of the present discus-
sion, but the changes documented in a
number of populations provide a useful
vantage point from which to review cer-
tain aspects of the aging process and
their role in determining the limits of the
human life span. As the demographic and
epidemiological transitions outlined in
this discussion progress, intrinsic factors
involved in the aging process itself will
gain importance with respect to their role
in limiting the length of the life span. It is
in this area of research that the most
promising evidence for genetic determi-
nants of human longevity will most likely
be found. Before focusing on the topic of
changes in body composition associated
with the aging process, however, one of
the peculiarities of the patterns seen in
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TABLE 4
PREDICTED AGE AT DEATH FOR VARIOUS AGES COMPARING U.S. DATA FOR 1995 AND 1996 –
ALL RACES AND ETHNIC GROUPS COMBINED
Life expectancy
Males Females
Age 1995 1996 PAD INCR 1995 1996 PAD INCR
0 72.5 73.0 73.0 – 78.9 79.0 79.0 –
1 72.1 72.6 73.6 0.6 78.5 78.6 79.6 0.6
5 68.3 68.7 73.7 0.1 74.6 74.7 79.7 0.1
10 63.3 63.8 73.8 0.1 69.7 69.7 79.7 0
15 58.4 58.9 73.9 0.1 64.7 64.8 79.8 0.1
20 53.8 54.2 74.2 0.3 59.9 59.9 79.9 0.1
25 49.2 49.6 74.6 0.4 55.0 55.1 80.1 0.2
30 44.6 44.9 74.9 0.3 50.2 50.2 80.2 0.1
35 40.1 40.4 75.4 0.5 45.4 45.4 80.4 0.2
40 35.6 35.9 75.9 0.5 40.7 40.7 80.7 0.3
45 31.3 31.5 76.5 0.6 36.0 36.0 81.0 0.3
50 27.0 27.1 77.1 0.6 31.4 31.5 81.5 0.5
55 22.9 23.0 78.0 0.9 27.0 27.1 82.1 0.6
60 19.1 19.2 79.2 1.2 22.9 22.9 82.9 0.8
65 15.6 15.7 80.7 1.5 18.9 18.9 83.9 1.0
70 12.4 12.5 82.5 1.8 15.3 15.3 85.3 1.4
75 9.7 9.8 84.8 2.3 11.9 11.9 86.9 1.6
80 7.2 7.3 87.3 2.5 8.9 8.9 88.9 2.0
85 5.2 5.4 90.4 3.1 6.3 6.4 91.4 2.5
PAD = Predicted age at death; INCR = Added life expectancy from preceding age group
the increase in predicted age at death
should be noted.
As was pointed out in the discussion of
the increments in predicted age at death,
the advantage enjoyed by women with re-
spect to life expectancy is the greatest at
birth and, using 1996 statistics for all
races, shrinks from six years to only one
year at age 85. Equally interesting is
comparison of the increase in life expec-
tancies experienced by Americans of Afri-
can origin with that experienced by indi-
viduals of European origin shown in Ta-
ble 5.
The comparisons in Table 5 reveal
some striking aspects of the demographic
transition presently in process in the
United States. First, the sex difference in
life expectancy at birth in the African
American population (8.1 years) is more
pronounced than among the population
at large (6.0 years), and in the population
of European ancestry (5.8 years). How-
ever, at age 85, the disparity has shrunk
to only one year just as it has among
those of European descent. Most notable
is the fact that the predicted age at death
for male Americans of European descent
is identical to that predicted for males of
African descent. The same holds true for
females.
Included among the explanations of-
fered for this observation are those posit-
ing a genetically determined tendency to
longer life span among individuals of Af-
rican descent. Variations of this explana-
tion posit the action of strong selection in
the early stages of life when high infant
and child mortality rates prevail. The
survivors of this process are those indi-
viduals fortunate enough to possess an
effective immune response and other at-
tributes conducive to survival in a rigor-
ously stressful environment. The pheno-
menon of »selective survival« under such
circumstances, repeated over many gen-
erations would favor retention of genes
beneficial under the prevailing condi-
tions. Eventually, the genome of the pop-
ulation could be expected to reflect these
adaptations. Future trends in these sta-
tistical measures along with continued
convergence of the socioeconomic status
of racial groups in the United States pro-
mise to provide useful clues in the search
for genetic determinants of longevity.
Emerging patterns of mortality
As infectious and major chronic de-
generative diseases account for fewer of
the deaths in industrialized populations,
what will take their place? Even if life ex-
pectancies continue to increase, there are
limits to the life spans of all known me-
tazoan organisms. It should be stressed
that, despite convincing evidence that in-
dividual cells age and lose their ability to
divide because of telomeric shortening14,
it is highly unlikely that there is any sin-
gle underlying mechanism that determi-
nes the rate of senescence and the age at
death. Rather, the occurrence of many
small failures occurring over time and ex-
erting a cumulative effect on the physio-
logical systems that maintain the organ-
ism is the more likely pattern leading to
senescence and death. Thus, close scru-
tiny of failures in these systems is neces-
sary to achieve greater understanding of
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TABLE 5
PREDICTED REMAINING YEARS OF LIFE AT
BIRTH AND AT AGE 85 FOR AMERICANS OF
EUROPEAN AND OF AFRICAN DESCENT
European-American
Age Men Women
1995 1996 1995 1996
0 73.4 73.8 79.6 79.6
85 5.2 5.3 6.3 6.3
African-American
Men Women
1995 1996 1995 1996
0 66.2 66.1 73.9 74.2
85 5.1 5.3 6.2 6.3
the limits of human longevity. If, for in-
stance, we use the generally accepted up-
per limit of the human life span of 120
years, it is possible to construct mathe-
matical models that parameterize the ac-
cumulation of such failures to produce
the observed curve of declining fitness.
This curve closely approximates the one
for observed survivorship rates cited ear-
lier15. What kind of physical changes are
associated with declining fitness? Ideally,
it should be possible to conduct serial
measurements of them in order to assess
the extent to which rate as well as the
type and extent of change signal decline
in fitness.
Changes in body composition provide
one such indicator of declining fitness3,16.
Simple anthropometric measurements
including stature, weight, circumferen-
tial dimensions and skinfold thickness re-
veal a great deal about the aging process.
With the addition of more intrusive (and
expensive), but more precise measures
such as bioelectric impedance, bone den-
sitometry, dual energy x-ray, magnetic re-
sonance, and computer assisted tomogra-
phy, it is possible to assemble a compre-
hensive record of the course of this impor-
tant aspect of the aging process. It is well
known that sustained and unintentional
weight loss is associated with a poor prog-
nosis in aging patients17. When subjected
to closer scrutiny, such weight loss usu-
ally involves loss of lean body mass. Al-
though it is not always possible to moni-
tor elderly patients using expensive dia-
gnostic instrumentation, anthropometric
measurements that can be used to esti-
mate lean body mass are usually feasi-
ble18–22.
At a time when the costs of health care
for the aging population are a matter of
national concern23, such relatively sim-
ple, low cost diagnostic procedures that
can be conducted by properly trained
non-physicians have much to recommend
them. In most cases, only cursory atten-
tion is given to the height and weight
measurements done in the physician's of-
fice. Little attention is paid to such as-
pects of standardization as removal of
shoes or other items of clothing. Circum-
ferential measurements and/or skinfolds
are seldom taken. Consequently, the phy-
sician usually relies upon the imprecise,
nonstandardized information placed in
the patient's file to supplement the im-
pressions gained during the physical ex-
amination. Moreover, the examination it-
self is usually brief and may not occur
more than once a year. Even the most
skilled and conscientious physician may
remain unaware of significant changes
under these circumstances. Regular mon-
itoring of indicators of change in body
composition by accredited anthropome-
trists could provide the physician with a
valuable diagnostic tool at relatively low
cost. If simple anthropometric procedures
reveal change exceeding normative stan-
dards, more intrusive measures would be
warranted. Such monitoring would facili-
tate early intervention, such as nutri-
tional counseling, to deal with conditions
that might otherwise eventually require
more expensive treatment.
Bone loss and aging
In a longitudinal study of bone density
change conducted at the University of Ar-
izona we have found high correlations be-
tween anthropometrically derived indices
such as the body mass index (BMI) and
measures of lean body mass and total
body fat. Other investigators18–22,24 have
developed a set of age and sex-specific
prediction formulas to estimate body
composition from bioelectric impedance
values and body mass index. These inves-
tigators have been able to demonstrate
that while these predictive equations are
quite reliable when applied to individuals
of a specific ethnic group, there are ethnic
differences in the relationship between
percent body fat and body mass index21,24.
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In the Arizona population, serial mea-
surements confirm that body mass index
increases through middle life and then
decreases. Both body mass index and
body surface area are highly correlated
with bone density in the later stages of
life.
Losses in bone density are observed in
both sexes as aging progresses. Although
it is widely believed that osteoporosis is
more prevalent in women, the problem is
one shared by both sexes by age 8025,26. In
the Arizona longitudinal study, the bone
density of every subject, male or female,
over age 90 had declined to a level well
within the generally accepted definition
of osteoporosis. While osteoporosis is not
one of the conditions included among the
leading causes of mortality, it is fre-
quently implicated in the rapid decline in
functional capacity preceding death. The
consequences of spinal and hip fractures
are especially debilitating. Non-trauma-
tic hip fractures in women are associated
with a mortality exceeding 20% within
the following year.
The consequences of spinal fractures,
although less easily linked to mortality,
have long been recognized as morbidity
factors. Depending upon the location of
the fracture and the number of vertebrae
involved, spinal fractures alter the curva-
tures that facilitate normal weight trans-
fer and thus often have pervasive effects
on locomotion and balance. Vertebral
crush fractures can reduce the length of
the spine appreciably, effectively reduc-
ing the space available for the viscera.
The effect on digestion and respiration
can impact the general state of health in
numerous ways, each of which can ulti-
mately result in mortality. If and when
cardiovascular disease and cancer are no
longer major causes of mortality, condi-
tions like osteoporosis, that progressively
and cumulatively reduce the individual's
functional capacity, will become ever
more important concerns for the health
care delivery system.
In many respects, conditions that cau-
se gradual decline in functional capacity
have the characteristics one would expect
in the aging process itself27. If the human
life span has limits, and if those limits
have an evolutionary history, it can be ex-
pected that such causes of mortality will
be far less susceptible to dramatic break-
throughs in intervention strategies. The
evolutionary value of individual death is
quite clear if one accepts the premise that
all species must be able to evolve in order
to survive and that resource limitations
will always place an upper limit on the
size of the population that is supportable.
When increased age is associated with
declining reproductive potential, as is
clearly the case for our species, the evolu-
tionary advantage accruing to the species
through timely death of the elderly is ex-
plicit. However, senescence is less easily
explained on evolutionary grounds. It
may be argued that conditions such as os-
teoporosis may be associated with senes-
cence because of antagonistic pleiotropies
wherein traits that enhance reproductive
success early in life have deleterious ef-
fects in later life. The physiology of bone
and its close association with maintenan-
ce of calcium homeostasis may provide an
example of such pleiotropy. If so, the asso-
ciation would necessarily involve endo-
crine factors, which would most certainly
include vitamin D and its metabolites.
Vitamin D: A steroid hormone
The importance of vitamin D in the
maintenance of calcium is well known.
The occurrence of rickets in children re-
ceiving insufficient sunshine exposure in
northern European countries was traced
to their incapacity to synthesize enough
of the vitamin through the long and clou-
dy winters at high latitudes. Dietary in-
take of vitamin D can compensate for its
low endogenous synthesis, as can be seen
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in the low incidence of rickets in northern
Europe today. However, the problem of
insufficient production of active vitamin
D still exists, although in a different seg-
ment of the population. Lack of outdoor
activity and, in recent times, concern
about the risk of skin cancer, lead to very
little sun exposure for some older people,
particularly those in nursing homes. Vi-
tamin D supplementation to prevent bo-
ne loss is now frequently recommended
under such circumstances28,29. However,
there is evidence that vitamin D supple-
mentation should be undertaken with
discretion. For instance, Moon et al.30 point
out that routine use of vitamin D as a
food supplement coincides with epidemic
onsets of atherosclerosis and osteoporo-
sis, and that excess vitamin D induces
both conditions in laboratory animals and
in humans.
The pathway of vitamin D synthesis,
starting in the skin with ultraviolet con-
version of ergosterol to cholecalciferol
and its conversion to active vitamin D3 by
hydroxylations in the liver and kidney
has also been known for a considerable
length of time. The best-understood as-
pect of vitamin D's role is its stimulation
of calcium uptake in the gut. This is af-
fected by direct action of the hormone
with nuclear DNA of cells of the intesti-
nal epithelium. The synthesis of messen-
ger RNA and the synthesis of a calcium
transport protein, calbindin, are the re-
sult. Calbindin binds to and transports
ionic calcium from the mucosal surface of
the intestinal epithelial cell to the serosal
side and releases it to diffuse across the
plasma membrane and into the blood.
Vitamin D also has a more rapid effect
on calcium absorption that has been
termed transcaltachia. This rapid form of
transport functions through the opening
up of channels in the membrane of intes-
tinal epithelial cells, is allowing calcium
to flow into the cell down a concentration
gradient. The rapidity of transcaltachia
compared to the DNA (genomic) pathway
derives from the fact that there is no de-
lay while the processes of transcription
and translation are carried out when
transcaltachia occurs. Transcaltachia does
not occur when serum calcium levels are
high. Consequently, the efficiency of cal-
cium absorption increases as serum cal-
cium level decreases31–34. Experiments
reported by Norman and his colleagues
yield convincing evidence that there are
two separate receptors for vitamin D on
the membrane of the intestinal epithelial
cell, one that mediates the genomic and
the other the non-genomic response35–41.
These investigators have also shown that
calcitriol stimulates the opening of cal-
cium channels in the plasma membranes
of certain target cells with the result be-
ing synthesis of osteocalcin by osteoblasts
and of kidney calcium binding protein, by
kidney cells.
Stimulation of membrane phospholi-
pid turnover with increased formation of
inositol 1,4,5-triphosphanate by calcitriol
in in vitro experiments in the same la-
boratory42, is evidence that one of vitamin
D's effects is the transduction of informa-
tion via G-proteins and second messen-
gers. The discovery of vitamin D recep-
tors on a wide range of cells, including
some cancer cells, is evidence that this vi-
tamin/hormone has many functions yet to
be discovered. DeLuca43 cites several
other known functions of vitamin D in-
cluding suppression of parathyroid hor-
mone release, (also reported in a recent
clinical trial in England)44 recruitment of
cells for osteoclast formation, develop-
ment of the skin, and regulation of as-
pects of female reproduction. It also has
the ability to regulate growth and differ-
entiation of epidermal keratinocytes and
active lymphocytes45, evidence of interre-
lationships between the skeletal and im-
mune systems.
Supplementing the diet with vitamin
D is now recognized as an important safe-
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guard against bone loss in the elderly.
However, the benefits are limited when
vitamin D is taken in its simple ergos-
terol form. This is the usual form of vita-
min D included in multiple vitamin prep-
arations, and it does have the effect of
lowering parathyroid hormone (PTH) lev-
els, thus mitigating the secondary hyper-
parathyroidism frequently associated
with osteoporosis. However, this effect is
most closely related to the presence of
calcidiol (25(OH) D2), not calcitriol (1,25
(OH)2 D3). In a recent study46, a high per-
centage of hospitalized patients were
found to have low blood calcidiol levels. In
fact, the same study showed similarly low
levels in a surprisingly high proportion
(42%) of younger patients. It has been es-
timated that 10–20% of older people in
the United States experience vitamin D
deficiency at least seasonally47–49. Euro-
pean populations also exhibit low calci-
diol levels, possibly because most dairy
products consumed there are not vita-
min-D fortified and multivitamin use is
less common50–52. There is strong eviden-
ce that vitamin D deficiency associated
with secondary hyperparathyroidism is
the major factor responsible for hip frac-
ture in the elderly, especially those who
are institutionalized or housebound53–57.
A supplement of 700–800 IU of ordinary
vitamin D precursor has a relatively mod-
est effect on the bone mineral content of
such long bones as the femur, but may re-
duce the incidence of hip fracture47,58,59.
There is evidence that some populations,
including Asians, may require higher
doses of vitamin D supplement to keep
PTH concentrations at normal levels60–62.
Despite its beneficial effects on circu-
lating PTH levels, ordinary vitamin D
supplementation only increases intesti-
nal absorption of calcium when taken in
very high doses63. In contrast, adminis-
tration of calcitriol increases absorption
at low doses, and has its greatest effect on
patients with the poorest intestinal cal-
cium absorption64. Therefore, to reduce
the risk of osteoporosis in postmenopau-
sal women and in older individuals who
do not respond to supplementation with
precursors, it may be necessary to pro-
vide active vitamin-D analogs, such as
calcitriol-hormone or alphacalcidiol65,66.
Osteoporosis patients of both sexes fre-
quently have poor intestinal absorption
of calcium, a condition that may indicate
intestinal resistance to vitamin D67.
Therefore, such conditions as inflamma-
tory bowel disease may play a role in the
etiology of osteoporosis because of their
impact on vitamin D activity in the gut68.
It does not appear that active vitamin D
analogs increase bone resorption, but are
necessary for the induction of cell differ-
entiation and the stimulation of osteo-
blasts69,70. Combining the administration
of active vitamin D analogs with medica-
tions, such as estrogen or bisphospha-
nates promises to enhance the effective-
ness of both71. It remains to be determi-
ned just how much the vitamin D recep-
tor genotype influences these effects72,73.
The binding of vitamin D to the plas-
ma membrane of target cells occurs at a
specific receptor that belongs to a family
of nuclear receptors for estrogens, gluco-
corticoids, retinoic acid and thyroxine. An
interesting question is: which of vitamin
D's many functions arose first and may
therefore be considered the primary func-
tion of vitamin D and its several active
analogs?
Calcium
Adequate calcium intake must be as-
sured to maintain physiological homeo-
stasis. However, the amount of calcium
that can be considered adequate is by no
means certain. There is much variation
in dietary calcium intakes of different
populations. Even within a single country
like China, reported daily calcium inta-
kes vary from a low of 230 mg to a high of
724 mg7,74,75. Such wide variation raises
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the possibility of early adaptations to low
intakes. Few if any populations achieve
the 1000 mg per day now recommended
for young women in the United States.
The advisability of regular calcium sup-
plementation remains a topic of consider-
able controversy. Calcium ingested in dai-
ry products, particularly before age 25, is
associated with higher bone densities in
women76. The efficacy of calcium supple-
mentation during pregnancy and lacta-
tion has long concerned obstetricians.
The physiological adjustments made at
these crucial times in female reproduc-
tive life give evidence of the importance of
calcium homeostasis for both mother and
child.
Half a liter of milk and 25 grams of
cheese per day will satisfy calcium re-
quirements for most people77. Other
foods, including broccoli, cabbage, beans,
and several dark green leafy vegetables
including collard and mustard greens are
good sources of calcium for those who
must avoid dairy products. Fish, such as
salmon or sardines consumed with bones
also provide dietary calcium without high
fat intake. Elderly female lacto-ovovege-
tarians have been found to maintain bone
density as well as omnivores at a calcium
intake 25% below the omnivore level78.
Not all calcium supplements are consid-
ered safe. Lead contamination in bone
meal and dolomite supplements and even
in some oyster shell supplements, al-
though not at toxic levels, may have an
unknown cumulative effect. There is con-
siderable evidence that calcium intake
early in life is positively correlated with
peak bone mass79,80.
Much of the controversy over recom-
mended calcium intake is focused on the
benefits of calcium supplements later in
life81. Several large studies have shown
no positive effect of calcium intake on the
rate of bone mineral decline with
aging78,82–85. Another study86 found that
calcium supplementation may play an
important role in potentiating the benefi-
cial effects of estrogen on bone mineral
turnover.
Without other forms of supplementa-
tion or medication, moderate calcium
supplementation, i.e. 500–1000 mg/day,
may reduce bone resorption by no more
than about 10% in postmenopausal wo-
men87. However, when coupled with vita-
min D supplementation, high-dose (1,500
–2,000 mg/day) calcium supplementation
can produce a 30–60% decrease in bone
turnover88. Moreover, because calcium
tends to decrease the amount of circulat-
ing 1,25 vitamin D, it has the potential to
increase the risk of certain types of can-
cer. One study89 found evidence that high
dosage calcium supplementation in men
was associated with increased risk of pro-
state cancer. As a general rule, it seems
advisable that calcium supplements be
accompanied by vitamin D to avoid such
undesirable side effects. It has been shown
that high-dosage calcium supplementa-
tion reduces zinc absorption and may
therefore require increased zinc intake90.
There is substantial disagreement con-
cerning the effect of calcium supplemen-
tation on the absorption of non-heme
iron. Some investigators, using the level
of serum ferritin as the indicator of iron
absorption, report no difference between
subjects receiving high calcium intakes
and those with low intakes91,92. Other in-
vestigators, using direct measurement of
iron absorption, report that high calcium
intakes reduce iron absorption significan-
tly, and that adolescents, and pregnant
and lactating women should restrict cal-
cium intake at meals in which iron intake
is also important93.
High protein diets increase the level of
calcium excretion94–97. The reason for this
is thought to be the increased acidity of
the urine associated with a high protein
diet. A more acidic urine leads to increa-
sed excretion of calcium98–100. Excessive
urinary calcium loss upsets calcium ho-
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meostasis, leading to bone resorp-
tion101–105. This happens because high
acidity requires buffering and calcium is
an important buffer98,106. Increased acid
secretion by the kidney is largely the re-
sult of oxidation of the sulfur-containing
amino acids methionine and cysteine,
abundant in animal proteins107–109. The
association between dietary protein in-
take and urinary calcium loss has been
shown to be linear110. Thus, lifelong in-
takes of acid-ash foods as in many West-
ern diets may be an important risk factor
for osteoporosis104,111,112. Avoidance of this
demand for calcium buffering may be in-
strumental in the superior bone densities
maintained by vegetarians113–117. Cross-
cultural comparisons have found a strong
association between diets high in animal
protein and incidence of hip fractu-
re75,111,118.
While the pattern of bone loss in fe-
males conforms to expectations based on
endocrinological changes occurring with
age, male bone loss is less clearly defined.
It is quite likely that estrogen plays a sig-
nificant role in male bone metabolism in-
dependent of testosterone. One indicator
of the importance of estrogen is the fact
that male bone mineral density is more
highly correlated with serum estrogen
than with testosterone119. There is con-
siderable evidence that male bones frac-
ture at a higher bone density than those
of women, and that the prevalence of ver-
tebral fractures is actually higher in
men120. Cody et al.121 report a different
pattern of bone loss associated with frac-
tures of the femoral neck occurring in
men from that seen in women. In men,
bone density was found to decrease throu-
ghout the proximal femur. In women a
combination of localized changes includ-
ing loss of trabecular bone at the fracture
site as well as decreased cortical bone at
the point of impact was most common.
Women lose more height proportionally
than men as they age, and the beneficial
effects of regular physical exercise in at-
tenuating loss of stature are more pro-
nounced in men than in women122. How-
ever, women with non-insulin dependent
diabetes mellitus appear to maintain
greater more bone density than non-dia-
betic women. No such difference between
diabetic and non-diabetic men has been
reported123. Davies et al.124 report an in-
teresting negative association between
calcium intakes and body mass index in
women, a relationship that has not to
date been reported for males.
Male bone loss
In a recently reported Spanish study
of healthy elderly men, multiple regres-
sion analysis of the relationships of bone
density to hormonal and anthropometric
variables indicates that body weight, sex
hormone binding globulin (SHBG), and
intact PTH levels are independent pre-
dictors of bone mass. However, most of
the bone mineral density was explained
by body weight alone. After adjusting for
age and BMI, SHBG and insulin-like
growth factor 1 found to be negatively
correlated with bone density125. There
seems to be little doubt that age-related
changes in androgen levels have an im-
pact on bone metabolism in males as well
as in females.
However, the nature of the relation-
ships between estrogenic hormones and
testosterone is far from clear. This uncer-
tainty is reflected in the conflicting re-
sults reported by investigators concerned
with the causes of bone loss in aging men.
For instance, contrary to Khosla, Melton
and Riggs' previously cited report119 that
estrogen levels are more highly corre-
lated with bone density than testosterone
levels in men, other investigators126 re-
port that testosterone levels are the most
reliable predictors of bone loss. Rapado et
al.127 found no significant correlation be-
tween male sex hormone and decrease in
hip bone mineral density (BMD), and Bo-
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onen et al.128 found that both serum tes-
tosterone and hydroxyvitamin D, and
dihydroxyvitamin D were all decreased in
hip fracture patients. Combined adminis-
tration of vitamins D3 and K2 has been
found effective in increasing the bone
mineral density of the lumbar spine in
women with osteoporosis129.
Testosterone replacement therapy has
been shown to increase bone formation in
men diagnosed with idiopathic hypogo-
nadotrophic hypogonadism, although bo-
ne resorption also increases in these pa-
tients130,131. However, Medras, Jankow-
ska, and Rogucka132 report that even when
long-term testosterone replacement ther-
apy succeeds in normalizing serum an-
drogen levels, elimination of osteopenia
does not always occur. The com- plex in-
teractions between sex hormones, body
composition and behavioral133,134 make it
extremely difficult to trace direct cause/
effect associations between changes in
androgen production and bone mineral
metabolism.
Vitamin D receptors
The role of the vitamin D receptor ge-
notype in predisposition to osteoporosis
remains under investigation. Vitamin D,
its metabolites and homologues are well
known to have many physiological ef-
fects. With respect to the maintenance of
bone density, one of the most important
and best-understood functions of vitamin
D is its regulation of calcium absorption
in the small intestine. The most active
form of vitamin D in this regulatory func-
tion is 1,25 (OH)2 vitamin D3 (calcitriol).
The receptors for this hormone have sev-
eral known variants, one of which arises
from a substitution of a guanine for an
adenine at the 3731st position from the 5'
end135. The G- allele exhibits reduced
transcriptional activity in promoter re-
gion and reduced calcium absorption.
Postmenopausal women homozygous for
the G-allele was found to have a 12%
lower BMD in the lumbar spine than
homozygotes for the A-allele. Interactions
between alleles at the vitamin D nuclear
receptor (VDR) locus and alleles at the es-
trogen receptor (ER) locus, which is also
polymorphic, are now thought to underlie
some of the subtle variation in bone den-
sities found when either VDR or ER geno-
types are independently examined136.
The best understood function of vita-
min D is by way of a nuclear receptor
(VDR) within the target cell. In this re-
spect, vitamin functions through the
same mechanism as other members of
the steroid-thyroid hormone superfamily.
The VDR, in turn, binds to the direct re-
peat response elements (DR-3) in the pro-
moter region of target genes to stimulate
or suppress transcription of mRNA. After
ribosomal translation, the result is syn-
thesis of proteins that perform a wide ar-
ray of functions. Of particular interest is
the recent discovery of vitamin D's role in
the immune response, where its function
may be that of a suppressor. Evidence for
this role has been found in experiments
with mice in which autoimmune condi-
tions have been treated successfully with
vitamin D and its analogs138.
The vitamin D receptor is one of a
family of receptors of various hydropho-
bic ligands. These ligands include, be-
sides vitamin D, other steroids, retinoic
acid, and thyroid hormone. All of the nu-
clear receptors are composed of several
domains necessary for transcription to oc-
cur. There is the aforementioned domain
for DNA binding (the C domain), plus a
domain for hormone binding, (the D do-
main), and a domain for dimerization
(the E domain). These domains could
have evolved through gene duplication
from a common ancestor. They also could
have come from different independent
sources.
On the basis of phylogenetic trees de-
veloped from two different domains of 30
nuclear receptor genes, Laudet et al.139
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conclude that both duplication and swap-
ping between domains of different origin
occurred. It appears that the first nuclear
receptor was one able to bind to DNA as a
homodimer. This receptor appeared very
early, probably around the time of origin
of all metazoan phyla. Later, a period of
diversification commencing with the ori-
gin of the vertebrates produced the vari-
ety of nuclear receptors present in con-
temporary species140. The close homology
between the vertebrate retinoid receptor
and that of Drosophila is strong evidence
of the existence of these receptors before
the divergence of vertebrates and inver-
tebrates.
Sex differences in fracture incidence
In both sexes, the frequency of frac-
ture occurrence is negatively correlated
with BMD, BMI, muscle strength, and
level of physical activity141–143. However,
the structural basis for bone density loss
in men may differ from that in women144.
Male periosteal expansion exceeds female
during growth and development. An im-
portant component of certain racial dif-
ferences in bone density results from sim-
ilar differences in the early acquisition of
bone density. Blacks, both male and fe-
male, experience greater periosteal ex-
pansion early in life, and therefore have
greater bone density than age- and sex-
matched whites. One result of greater
periosteal expansion is wider long bones
in early adulthood. Structurally, this ex-
pansion places cortical bone mineral
mass at a greater distance from the neu-
tral axis of the bone in men than in wo-
men and in blacks than in whites. Place-
ment of bone mineral mass at a greater
distance from the neutral axis of the bone
confers a mechanical advantage that en-
hances the strength of long bones, espe-
cially in resistance to torsional stress.
One result of this increase in strength is a
lowered risk of non-traumatic fracture.
Consequently, at peak bone density, both
racial and gender differences in bone
strength are likely attributable to size
and not BMD.
The loss of trabecular bone is similar
in both sexes, but women experience
greater loss of connectivity, the important
relationship between the struts and pla-
tes that maintains the structural integ-
rity of the trabeculae. In addition, endo-
cortical resorption is greater in women.
Men lose less cortical width for that rea-
son and because of a greater amount of
subperiosteal apposition during aging.
Men who suffer fractures of the spine
have smaller vertebral width120 and men
with hip fractures have a narrower femo-
ral neck. Nonetheless, the average de-
cline in density of the radius experienced
by men between the ages of 29 and 76 is
about 1% per year145. Ultrasound deter-
minations of bone density in the calca-
neus have proven effective in predicting
fracture risk in men146 despite the differ-
ence between the structural and func-
tional characteristics of the bones of the
forearm and the heel.
Materials and Methods
The Arizona Bone Density Study was
initiated in 1982. The first cohort of sub-
jects was drawn from the Volunteer Asso-
ciation of the Walter O. Boswell Memorial
Hospital in Sun City, Arizona. These sub-
jects were, by and large, retirees. Most
owned their own homes and were finan-
cially independent. Almost all were of Eu-
ropean ancestry. In order to broaden the
demographics of the study, a second co-
hort was recruited from residents of pub-
licly subsidized retirement housing in
Tucson, Arizona. These subjects were, on
the average, less affluent than those from
Sun City. Also, most of the Tucson sub-
jects had been Arizona residents for a lon-
ger period of time, often since birth, and
roughly 30% of them were of Hispanic ori-
gin as compared to less than 5% in Sun
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City. A small sample of African American
subjects was also recruited in Tucson.
From the outset, more women than men
were recruited in both the Sun City and
Tucson populations. This sampling bias
reflected the belief, prevalent at the time,
that osteoporosis was primarily a condi-
tion-affecting woman.
The primary objective of the study was
to monitor changes in bone density over
time. However, other changes were moni-
tored as well. Height and weight were
measured on each occasion for all sub-
jects, and bioelectric impedance assess-
ments of body composition were conduc-
ted on a sample of 451, (277 men and 174
women) who were enrolled in the wheat
bran fiber and piroxicam clinical trials.
Alkaline phosphatase levels and concen-
trations of serum calcium and other min-
erals were also determined through the
analysis of blood samples from these sub-
jects. On each occasion, all subjects were
requested to complete questionnaires
containing questions about bone fracture
histories, medications, stress-inducing
experiences, exercise patterns, milk con-
sumption, and use of dietary supple-
ments. On the occasion of their first visit,
women were asked to complete an addi-
tional questionnaire concerning age at
menarche and menopause and reproduc-
tive and breast-feeding histories.
Subjects
From 1982 through 1998 data were
collected annually at both Sun City and
Tucson. Since the average age of the sub-
jects of the first cohort was 70 years, and
the loss of subjects for various reasons
could be expected, new subjects were
added each year. By the end of 1998, the
total sample was 5,475 (4,121 women and
1,354 men). One hundred and seventy
three subjects, (126 women and 47 men)
participated for 10 years or more. Over
the course of the study, subjects from sev-
eral rural communities in Pinal County,
Arizona (Casa Grande, Eloy, and Flor-
ence) had been incorporated in the study
population, as had subjects enrolled in
wheat bran fiber and piroxicam colon
cancer prevention clinical trials conduc-
ted in Sun City and Tucson.
Methods
Annual scans of the left radius were
conducted using single-beam photon ab-
sorptiometry (Lunar Radiation SP-1 and
SP-2 Bone Densitometers). While both
dual-photon and dual-energy x-ray
(DEXA) instruments provide more infor-
mation about clinically-sensitive areas
such as the lumbar spine and the femoral
neck, the objective of comparing serial
measurements of cortical bone density
was satisfactorily achieved using the sin-
gle photon devices. The portability of the
single photon device was a major consid-
eration in its favor, because in order to
reach the target populations of the Ari-
zona study, it was necessary to set up the
equipment at a number of sites in several
cities and in rural areas. Change in corti-
cal bone density over time can be mea-
sured with a high degree of accuracy at
the radial site using single-beam photon
absorptiometry (SPA). Since cortical bone
makes up more than 80% of the total
bone mass of the adult, the SPA scanning
of this bone as a surrogate for whole-body
scanning yields useful results.
Within this limited context, SPA bone
scans are a highly reliable method for ef-
fecting valid assessments of cortical bone
density. When suitable safeguards are
taken to assure that all scans are taken
at precisely the same site; the method is
ideal for the monitoring of bone density
change through serial measurements.
Thus, when used as a research method
for a large sample, mixed longitudinal
study of bone density change it is a very
powerful tool. However, its clinical use as
a predictor of fractures at sites where
trabecular bone is more abundant cannot
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be recommended. Since the objectives of
the present study did not include esti-
mates of trabecular bone density or chan-
ges thereof, the advantages of SPA meth-
odology considerably outweighed its dis-
advantages. Results of a comparative
study involving subjects drawn from the
Arizona Bone Density Study, yielded a
correlation of 89% between the values for
whole-body bone density attained by
DEXA measurement and the values for
bone density of the distal one-third site of
the radius attained through SPA measu-
rement147. An additional advantage of the
SPA method is that the highly collimated
photon stream emitted by its 200 mC125 I
source produces a very low radiation dose
for the subject, and its low scatter mini-
mizes the risk of radiation to both sub-
jects and investigators.
The measurement of stature to the
nearest millimeter was done using a free-
standing field anthropometer with the
subject shoeless. Weight in kilograms
was taken using a portable medical scale.
The same anthropometrist took each of
these measurements on each scanning oc-
casion throughout the study. Body mass
index was calculated using the equation:
BMI = weight (kg)/ height (m)2. More than
14,000 records of these measurements as
well as bone scan reports, human sub-
jects' consent forms and questionnaires
remain on file in The Biological Anthro-
pology Laboratory at the University of
Arizona.
Results
Table 6 shows the values for bone den-
sity and body mass index arranged by
five-year categories for a sample of 4,036
women and 1,264 men for whom complete
records are available. The values that ap-
pear in this table represent those ob-
tained at each subject's final examina-
tion. In some instances, this may be the
last of 16 such measurements and in oth-
ers it is the first and only one. The values
shown in this table therefore represent a
purely cross-sectional database.
As the values in Table 6 indicate, aver-
age cortical bone density declines steadily
from age 50 onwards in women. The rela-
tively small sample of men in the 50–55
year age group would appear to experi-
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TABLE 6
FINAL BONE DENSITIES AND BODY MASS INDEX VALUES FOR TUCSON AND SUN CITY
WOMEN AND MEN
Bone density Body mass index
Age Women (N) Men (N) Women Men
< 50 0.6591 (369) 0.7803 (50) 25.79 26.12
50–55 0.6532 (142) 0.7468 (20) 27.36 29.30
55–60 0.6188 (202) 0.7553 (38) 26.97 27.58
60–65 0.5908 (332) 0.7502 (84) 26.17 27.40
65–70 0.5585 (684) 0.7279 (208) 26.16 26.91
70–75 0.5295 (808) 0.7157 (286) 25.79 26.70
75–80 0.4946 (708) 0.7054 (295) 25.34 26.92
80–85 0.4773 (497) 0.6763 (183) 24.94 25.17
85–90 0.4512 (246) 0.6341 (81) 24.31 24.21
90–95 0.4161 (69) 0.5817 (18) 23.58 24.72
95–100 0.3966 (11) 0.4106 (1) 23.26 23.30
ence a sharp decrease in bone density, but
it is probable that the apparent accelera-
tion of bone density decrease is an arti-
fact of small sample size in this age
group. Succeeding age groups exhibit a
rate of decline similar to that seen in the
values for women. The decline in bone
density in both sexes is sufficient to dis-
pel the widely held notion that bone den-
sity decrease is primarily a women’s pro-
blem. However, the lower average bone
densities characteristic of women through-
out early adulthood, coupled with a pe-
riod of accelerated bone loss at menopau-
se make them susceptible to bone fractu-
res at an earlier age than men.
Bone density values obtained through
single SPA are expressed as grams of
bone mineral per square centimeter of
area. However, these values can be used
to estimate the three-dimensional config-
uration of the radial diaphysis, and, by
applying certain assumptions, the cross-
sectional areas of the cortex and medul-
lary cavity can be estimated. The method
used in making these estimates is de-
scribed in detail elsewhere148. Normal re-
modeling of the diaphysis of long bones
such as the radius usually involves re-
sorption at the endosteal surface and ap-
positional growth at the subperiosteal
surface. With increasing age, the deposit
of new bone at the subperiosteal surface
declines while resorption at the endosteal
surface continues. The result is a thin-
ning of the cortex. In its earlier stages,
the increased cross sectional area of the
diaphysis may confer an advantage in
withstanding torsional stress. However,
thinning of the cortex eventually leads to
increased vulnerability to fractures pro-
duced by buckling of the cortex. There-
fore, estimation of changes in the ratio of
cortical area to total cross sectional area
(PCA) of the radius provides a useful
means of estimating the risk of fracture
in the radius. Table 7 shows the average
initial and final values for PCA for wo-
men and men.
As can be seen from the values for
PCA in Table 7, women enter the post-
menopausal period with PCA values as
high or higher than those of men. How-
ever, they are already experiencing a de-
cline in cortical area in the 50–55 year
age interval, while men show little chan-
ge until the 65–70 year interval. Because
of the differences in age of onset and rate
of decrease in PCA, initial values for men
in the 80–85 year age group are higher
than those for women in the 65–70 year
age group. The rate of loss in the later
years of life, however, is very similar in
both sexes.
41
W. A. Stini: Sex Differences in Bone Loss, Coll. Antropol. 27 (2003) 1: 23–46
TABLE 7
INITIAL AND FINAL PERCENT CORTICAL AREA – SEXES COMPARED
Age Women Men
Initial PCA Final PCA Initial PCA Final PCA
50–55 64.6 63.5 61.0 61.0
55–60 59.5 58.6 59.3 59.1
60–65 58.0 57.4 59.1 59.1
65–70 54.5 53.3 58.0 57.3
70–75 52.4 50.5 57.9 56.6
75–80 49.0 47.0 57.4 55.7
80–85 48.7 45.5 54.8 52.8
85–90 46.0 43.1 54.3 49.8
90–95 42.6 39.1 50.4 45.9
Relationships between body mass in-
dex and PCA at various ages are shown in
Table 8. In Table 8, BMI values conven-
tionally used to assign the designations
»obese« (BMI>28.0), and »excessively
lean« (BMI<20.0) were applied to average
values in the 10-year age categories: 60–
70, 70–80, and 80–90, to assess the rela-
tionship between extreme BMI values
and PCA. Along with the aforementioned
decline in PCA with age, the PCA values
for subjects of both sexes with high BMI
values are seen to be substantially higher
than for those with low BMI values.
When the values for PCA, bone min-
eral content and bone density for subjects
drawn from the low BMI (n=370) and
high BMI (n=1228) categories are com-
pared, the differences for all three of
these indicators of bone fracture risk are
highly significant (p<0.0001). This is true
of all age categories whether calculated
by sex or with sexes combined. Analysis
of variance to test the relationship of PCA
to BMI at all ages yields an F value of
91.9 (p<0.0001), sexes combined. Sepa-
rate analyses of variance for the male and
the female samples yield F values of 15.5
and 65.9 respectively, both also signifi-
cant at the p<0.0001 level.
Normative bone density values, devel-
oped from a number of studies conducted
in various geographic areas of the United
States, are consistently higher than the
averages for each age group for both
sexes in the Arizona study. When the
mean percent of the national normative
values for Arizona subjects is compared
to their mean BMI values, a t-test yields
a 2-tailed significance <0.0001, similar to
the level of significance for the compari-
son of means for body mass index and
percent of peak bone density.
Discussion
The physiological roles of vitamin D
are many and varied. Indeed, its original
function may well have had nothing to do
with the maintenance of bone. Vitamin D
is a steroid hormone, and it should come
as no surprise that some of its effects may
differ in males and females. There is no
question that the maintenance of the in-
tegrity of the skeleton is important to
survival. But the skeleton's role as a res-
ervoir of calcium is sometimes more im-
portant than its structural one. There-
fore, the demands of reproduction may on
occasion require the sacrifice of bone
mass even though the risk of fractures is
increased. The demands of pregnancy
and lactation experienced by women have
no parallel in men. »Osteoporosis of preg-
nancy« and a surprisingly rapid recovery
of normal bone density is a well-known
occurrence. The mobilization of bone cal-
cium is necessary to support the needs of
the fetus and infant. When adequate cal-
cium is available in the diet, increased in-
testinal absorption efficiency can compen-
sate for the increased demand. However,
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TABLE 8
PCA VALUES IN THREE AGE GROUPS AND
BY BMI CATEGORY
Female
X (N)
Male
X (N)
Age group 60–70
Average BMI 26.1 26.7
Average PCA 54.6 (928) 57.9 (212)
PCA (BMI > 28) 56.9 (288) 58.7 (62)
PCA (BMI < 20) 50.4 (60) 54.5 (5)
Age group 70–80
Average BMI 25.6 26.8
Average PCA 48.9 (1,423) 56.2 (418)
PCA (BMI > 28) 51.2 (348) 56.7 (147)
PCA (BMI < 20) 45.8 (115) 52.9 (12)
Age group 80–90
Average BMI 24.8 24.8
Average PCA 44.7 (732) 51.9 (250)
PCA (BMI > 28) 47.8 (144) 53.6 (36)
PCA (BMI < 20) 41.4 (86) 45.1 (15)
calcium intake frequently falls short,
with the result that skeletal calcium
must be mobilized. That the skeleton can
contribute a substantial amount of cal-
cium at this critical stage in the repro-
ductive process should come as no sur-
prise. What is surprising is the rapid
recovery that often occurs. Clearly, adap-
tations at the endocrine level are invo-
ked.
When menopause occurs, the finely-
tuned mechanisms that make this recov-
ery possible no longer occur. Consequent-
ly, the ability to resorb bone mineral that
is adaptive early in life becomes mal-
adaptive after the endocrinological chan-
ges associated with menopause have oc-
curred. These are the characteristics
expected of antagonistic pleiotropy. The
detailed pathways of these adjustments
are complicated and subject to consider-
able inter-individual variability. Never-
theless, efforts to understand them more
fully should yield both practical and theo-
retical rewards. In a future where the
leading causes of mortality are no longer
cardiovascular diseases and cancer, con-
ditions that arise from such senescent
changes will be a major concern for health
delivery systems around the world.
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SPOLNE RAZLIKE U GUBITKU KO[TANE MASE:
EVOLUCIJSKE PERSPEKTIVE JEDNOG KLINI^KOG PROBLEMA
S A @ E T A K
Dramati~an porast stanovni{tva u svijetu koji se pojavio tijekom zadnjih stotinu
godina u najve}oj je mjeri posljedica pada smrtnosti od infektivnih bolesti. Epidemio-
lo{ka tranzicija uzroka smrti prema degenerativnim stanjima, kao {to su kardiovas-
kularne bolesti i karcinomi, javlja se u industrijaliziranim zemljama, kao i u zemljama
u razvoju. U industrijaliziranim zemljama, demografski profili danas odra`avaju po-
rast u o~ekivanom trajanju `ivota za oba spola. No, o~ekivano trajanje `ivota kod `ena
je ve}e od onog za mu{karce za 6 i vi{e godina. Daljnje promjene u uzorku mortaliteta
pratit }e uspjeh u redukciji smrtnosti prouzrokovane degenerativnim stanjima kao {to
su kardiovaskularne bolesti i tumori. U 21. stolje}u, stanja koja su povezana sa stare-
njem bit }e od sve ve}e va`nosti. Adaptivne strategije koje su poja~avale reproduktivan
uspjeh tijekom najve}eg dijela evolucije ~ovjeka mogu se sada pokazati {tetnima za
ljudsko zdravlje kako prosje~no o~ekivano trajanje `ivota dosi`e besprimjernu du`inu.
U takvom okoli{u, razlike u mehanizmima pre`ivljavanja koje su razvili mu{karci u
odnosu na `ene postat }e sve va`nije.
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